9.59 USD
↘ 0.73 (7.07%)AT CLOSE (11:59 AM EDT)
Phathom Pharmaceuticals, Inc. Common Stock
PHATNASDAQ • USD
9.55
↘ 0.04 (0.42%)
POST MARKET (AS OF 07:57 PM EDT)
Post Market
AS OF 07:57 PM EDT
9.55
↘ 0.04 (0.42%)
Market: CLOSED
Open?$10.31
High?$10.45
Low?$9.50
Prev. Close?$10.32
Volume?1.7M
Avg. Volume?1.4M
VWAP?$9.78
Rel. Volume?1.21x
Bid / Ask
Bid?$9.50 × 100
Ask?$10.43 × 2.0K
Spread?$0.93
Midpoint?$9.97
Valuation & Ratios
Market Cap?764.9M
Shares Out?79.8M
Float?42.2M
Float %?53.5%
P/E Ratio?N/A
P/B Ratio?-2.27
EPS?-$1.97
Dividend?0.00%
Ex-Dividend?N/A
PHAT is currently priced at $9.59. Both sides of the analysis point lower: technicals flash "Strong Sell" and fundamentals confirm with a "Sell" reading. This is driven by a concerning Altman Z-Score in the distress zone, exceptional Return on Equity (46.7%), a bearish Death Cross on the long-term moving averages and bearish long-term moving average alignment. On valuation, PHAT trades roughly in line with sector averages — neither particularly cheap nor expensive.
Technical & fundamental data as of May 29, 2026.
News
Profile
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.
Employees
371
Market Cap
823.1M
Industry
PHARMACEUTICAL PREPARATIONS
Website
Listed
2019-10-25
Address
100 CAMPUS DRIVE,
FLORHAM PARK, NJ 07932
Phone: (877) 742-8466
FLORHAM PARK, NJ 07932
Phone: (877) 742-8466
Technical OutlookStrong Sell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-3/3)
Medium-Term (Wave)?▼ Bearish(-3/3)
Short-Term (Ripple)?▼ Bearish(-3/3)
MA Alignment?Bearish Alignment
Full Technical Analysis →Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?23
Z-Score?0
Momentum?97
Short Sent.?40
Piotroski F-Score?3/9Weak
Altman Z-Score?-6.01Distress
Confidence?51%Low
Short InterestSqueeze Risk
Short % of Float?24.40%Squeeze Risk
Short Interest?10.3M
Days to Cover?8.7
Free Float42.2M
Avg Daily Volume1.2M
Settlement Date2026-05-15
Financial Health
Current Ratio?2.21Strong
Quick Ratio?2.16Strong
Cash Ratio?1.45Strong
Debt/Equity?-0.49Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score83/100
P/E?N/A▾
P/B?-2.27CHEAP▾
S&P97
P/S?3.73FAIR▾
Peers100
S&P41
P/FCF?N/A▾
EV/EBITDA?-7.8CHEAP▾
S&P97
EV/Sales?3.66FAIR▾
Peers100
S&P51
Returns & Efficiency
ROE?46.7%STRONG▾
Peers50
S&P91
ROA?-51.6%WEAK▾
S&P3
Cash Flow & Enterprise
FCF?$-97764000
Enterprise Value?$749.3M
Fundamentals ratios updated end of day